Dec 22, 2023 US Food and Drugs Administration (USFDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. TARPEYO was first approved…

Recent Post
- 🚨 CDSCO Issues Urgent Directive for Stopping manufacturing and marketed of Unapproved FDCs – What Pharma Manufacturers Need to Know
- 📊 Unlocking Opportunity: Comprehensive Market Research Reports Now Available at Vaayath Consulting
- 🌐Ease of Doing Business: CDSCO introduces new Updates regarding the Auto-generated Market standard Certificate (MSC) and Non-Conviction Certificate (NCC) for Licenced Medical devices.
- Complete List of Banned Drugs in India
- Government Mandates Online CRO Registration via SUGAM Portal!